HDAC inhibitors have been shown to combat aging-associated cognitive decline, as well as dopaminergic neuron loss and PD risk [15, 16], suggesting that they may protect against neurodegenerative disorders. This evidence concerns the gene HDAC9 and Parkinson disease.